Sichuan Kelun Pharmaceutical (SHE:002422) obtained the approval of China's National Medical Products Administration for the registration of paliperidone palmitate injection, according to a Shenzhen bourse filing on Saturday.
The Chinese pharmaceutical company's shares dropped less than 4% at the close of Monday's trade.
The company's subsidiary, Hunan Kelun Pharmaceutical, developed and manufactured the oral antipsychotic, which is used to treat schizophrenia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments